FGF21 and Other metabolic disease: Corroborating this, a previous review of publications reported that FGF21 is considered a biomarker of many metabolic diseases, and experimental studies have shown that the administration of FGF21 in obesity can reduce body weight, glucose and triglyceride, improve insulin sensitivity and increase the mass of brown adipose tissue (3,11).